DrugDashboards

Lisdexamfetamine Dimesylate

lisdexamfetamine · LISDEXAMFETAMINE DIMESYLATE 30 mg/1 · Capsule · Oral · Mylan Pharmaceuticals Inc.

NDC 00378-6856-77 · 90 CAPSULE in 1 BOTTLE, PLASTIC · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price is down 29% over the past year, to $2.66 per unit. It is in shortage right now. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$2.66per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$6.94per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$3.88per unitGolden State Medical Supply, Inc. · Aug 26, 2025146% of what pharmacies pay — higher than 67% of drugs with this benchmark
  • Medicaid generic ceiling (FUL)$2.66per CAPweighted avg manufacturer price $1.2258 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$5.00$10.00Oct 2023Sep 2026$2.66
36 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$79.92
#90 count
$239.76

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$1.4M
10,323 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

43● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 3 active manufacturers+10
  • in shortage now+25
  • price down 26% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for lisdexamfetamine (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA202835
TE code
AB
Approval date
Aug 25, 2023
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of lisdexamfetamine (Capsule)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals LLCLISDEXAMFETAMINE DIMESYLATE 10 mg/1Aug 27, 2026Sep 3, 2026
Amneal Pharmaceuticals LLCLISDEXAMFETAMINE DIMESYLATE 60 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCLISDEXAMFETAMINE DIMESYLATE 30 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCLISDEXAMFETAMINE DIMESYLATE 70 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCLISDEXAMFETAMINE DIMESYLATE 40 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCLISDEXAMFETAMINE DIMESYLATE 20 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCLISDEXAMFETAMINE DIMESYLATE 50 mg/1Jul 15, 2026Sep 2, 2026
AvKARELISDEXAMFETAMINE DIMESYLATE 20 mg/1Jul 15, 2026Sep 2, 2026
AvKARELISDEXAMFETAMINE DIMESYLATE 50 mg/1Jul 15, 2026Sep 2, 2026
AvKARELISDEXAMFETAMINE DIMESYLATE 30 mg/1Jul 15, 2026Sep 2, 2026
AvKARELISDEXAMFETAMINE DIMESYLATE 40 mg/1Jul 15, 2026Sep 2, 2026
AvKARELISDEXAMFETAMINE DIMESYLATE 70 mg/1Jul 15, 2026Sep 2, 2026
AvKARELISDEXAMFETAMINE DIMESYLATE 60 mg/1Jul 15, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.LISDEXAMFETAMINE DIMESYLATE 70 mg/1Jul 15, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.LISDEXAMFETAMINE DIMESYLATE 10 mg/1Jul 15, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.LISDEXAMFETAMINE DIMESYLATE 20 mg/1Jul 15, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.LISDEXAMFETAMINE DIMESYLATE 30 mg/1Jul 15, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.LISDEXAMFETAMINE DIMESYLATE 40 mg/1Jul 15, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.LISDEXAMFETAMINE DIMESYLATE 50 mg/1Jul 15, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.LISDEXAMFETAMINE DIMESYLATE 60 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Lisdexamfetamine Dimesylate — NDC 00378-6856-77," retrieved September 3, 2026, https://drugdashboards.com/drug/00378685677.

Free to cite with attribution — see how the data is put together.